Phase 3 N=196 Long-term Safety Extension to Study TRCA-301
Metabolic Acidosis
Primary: Incidence of Adverse Events, Serious Adverse Events, and Adverse Events Leading to Withdrawal. — 0; 1.2 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=61 Pain Control in Colorectal Surgery: Liposomal Bupivacaine Block Versus Intravenous Lidociane
Colorectal Disorders
Primary: Verbal Pain Scale (VRS) - 4 Week Post-op — 0.4; 1.1 score on a scale
Phase 4 N=22 Naltrexone and Bupropion Combination on Obese,Smoking Patients With Schizophrenia
Obese · Cigarette-smoking · Schizophrenia
Primary: Change From Baseline in Weight at 24 Weeks — 0.2; -0.9 kilogram
Phase 3 N=961 A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change in HbA1c — -2.0; -2.2; -1.9; -2.2 Percentage change — p=0.0003
Phase 1 N=44 A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma
B-cell Lymphoma
Primary: Part I: Number Of Participants Experiencing Treatment-emergent Adverse Events And Treatment-emergent Serious Adverse Events — 11; 10; 2; 2 Participants
Phase 3 N=152 Pilot Evaluation of Two Test Materials With a Positive Control When Used as a Patient Preoperative Skin Preparation
Bacteria Microflora Reduction
Primary: Change in Bacterial Microflora on the Inguinal Area — -3.7; -3.1; -3.5 log10 CFU
Phase 2 N=56 PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
Colon Cancer
Primary: Overall Response Rate — 32 percentage of participants
Phase 3 N=170 Comparative Study of Antimicrobial Effectiveness
Bacterial Microflora Reduction
Primary: Change in Bacterial Microflora on the Inguinal Area — -3.92; -3.69; -3.94 log10 CFU
N/A N=372 Bausch & Lomb Ophthalmic Viscosurgical Device (OVD) Dispersive (DVisc40)
Cataract
Primary: Percent Change in Mean Epithelial Cell Density (ECD) — -8.4; -6.8 percentage change in ECD
N/A N=5,484 An Observational Study of Follitropin Alpha Biosimilar: the Real-world Data
Reproductive Issues · Reproductive Disorder · Fertility Disorders
Primary: Number of Oocytes Retrieved — 8.6; 10.3; 10.5; 9.6 The total number of retrieved oocytes — p=<0.001
Phase 3 N=329 Preoperative Skin Preparation Study to Evaluate the Antimicrobial Capabilities of Four Test Substances
Surgical Site Infection
Primary: Change in Bacterial Microflora in the Inguinal Area — -3.86; -4.34; -3.65; -3.80 log10 CFU
Phase 3 N=268 Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)
Complicated Intra-abdominal Infections
Primary: Percentage of Participants With Clinical Response (Clinical Cure or Clinical Failure) at Test of Cure (TOC) Visit: Clinically Evaluable (CE) Population — 95.2; 93.1…
Phase 3 N=16 Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age
Cystic Fibrosis
Primary: Part A: Maximum Observed Plasma Concentration (Cmax) of ELX, TEZ, and IVA — 6.13; 6.93; 1.01 microgram per milliliter (mcg/mL)
Phase 2 N=95 A Phase 2 RCT Study of CX-8998 for Essential Tremor
Essential Tremor
Primary: Baseline and Day 28 on The Essential Tremor Rating Assessment Scale Performance Subscale (TETRAS-PS) Total Score — 22.7; 22.8; 21.1; 20.7 score on a scale
N/A N=225 Improving the Behavioural Impact of Air Quality Alerts
Pollution; Exposure · Health Behavior
Primary: Adoption of Protective Behaviour at 4 Weeks — 3.67; 4.25; 4.29; 3.65 units on a scale 1-9 — p=.964